SFS
ARQT icon

Sowell Financial Services’s Arcutis Biotherapeutics ARQT Stock Holding History

Sowell Financial Services’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-282
Closed -$9K – 659
2021
Q1 		$9K Sell
282
-66
-19% -$2.06K ﹤0.01% 2352
2020
Q4 		$10K Buy
+348
New +$8.52K ﹤0.01% 1994

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Sowell Financial Services's ARQT Position: Q2 2021 in Review

Sowell Financial Services sold out of Arcutis Biotherapeutics (ARQT) in Q2 2021, closing a stake of 282 shares — an estimated $9K sold.

Sowell Financial Services first reported a position in ARQT in Q4 2020 and held it in 2 quarters. The position peaked at $10K in Q4 2020. 102 funds tracked by Wall St. Rank hold ARQT as of Q2 2021.

  • Sowell Financial Services reported no remaining Arcutis Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 282 Arcutis Biotherapeutics shares in Q2 2021, an estimated $9K.
  • Sowell Financial Services first reported a position in Arcutis Biotherapeutics in Q4 2020 and held it in 2 quarters.
  • Sowell Financial Services's Arcutis Biotherapeutics position peaked at $10K in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.